Alexion Pharmaceuticals PT Raised to $161.00 at Canaccord Genuity (ALXN)
Analysts at Canaccord Genuity lifted their price target on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $138.00 to $161.00 in a research report issued to clients and investors on Monday, American Banking News reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective indicates a potential upside of 23.98% from the company’s current price.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.41% during mid-day trading on Monday, hitting $129.86. The stock had a trading volume of 1,088,027 shares. Alexion Pharmaceuticals has a 1-year low of $81.82 and a 1-year high of $134.27. The stock’s 50-day moving average is $125.7 and its 200-day moving average is $114.1. The company has a market cap of $25.462 billion and a price-to-earnings ratio of 74.50.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, October 24th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter last year, the company posted $0.60 earnings per share. Alexion Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on ALXN. Analysts at Goldman Sachs Group Inc. downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Separately, analysts at Piper Jaffray initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $172.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alexion Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, November 15th. They now have a $126.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $128.50.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.